Abstract-Recent, rapid progress in the molecular biology of serotonin (5HT) receptors requires conceptual re-thinking with respect to receptor classification. Thus, based on operational criteria (agonist and antagonist rank order), as well as transduction mechanisms involved and the structure of the receptor protein, the Nomenclature Committee of the Serotonin Club has proposed the following classification and nomenclature: the main receptor types 5-HT, to S-HT4, recombinant receptors (e.g. 5-ht, to 5-ht7) and 'orphan' receptors. The aim of the present review is to discuss the events leading to this classification, the criteria for and functional responses mediated by various 5-HT receptors, as well as the therapeutic possibilities with 5-HT ligands.
5-HT) is a neurotransmitter in the CNS, but is also present in particularly high concentrations in blood platelets and the enterochromaffin cells of gastrointestinal mucosa. Though the vasoconstrictor properties of defibrinated blood and blood serum were long known (Ludwig and Schmidt, 1868) , it was only in 1948 that Page (1958) succeeded in isolating a crystalline complex 'serotonin' from the blood serum (Rapport et al., 1948) ; the active moiety of this complex was found to be 5-HT (Rapport, 1949) . In the 1930s Erspamer and colleagues became involved in the characterization of 'enteramine' from the enterochromaffin cells in the gastrointestinal tract (see Erspamer, 1954) . Subsequently, 'enteramine' was also identified as 5-HT and the chemical identity of the natural and synthetic serotonin was backed by the similarity of pharmacological profile, such as contraction of the sheep carotid artery, guinea-pig, mouse and rabbit jejunum, rat and cat uterus and cat nictitating membrane, triphasic blood pressure response and antagonism by yohimbine and potentiation by cocaine of the sheep carotid artery contraction (Erspamer, 1954; Page, 1958) . Thus, the scene was set for the characterization of serotonin receptors. Woolley and Shaw (1953a,b) and Page and McCubbin (1953) reported that the vascular responses to serotonin could be antagonized by several drugs including some tryptamine derivatives. Caddum (1953) found that the guinea-pig isolated ileum was selectively desensitized to serotonin or substance P by high concentrations of these substances, suggesting that the two compounds activated different receptor populations. The serotonin-induced contraction of the guinea-pig ileum was not affected by drugs such as diphenhydramine, nicotine (high doses), hexamethonium or decamethonium, but was partially suppressed by atropine and cocaine, as well as by its own repeated administration, at which time the responses to histamine, acetylcholine, pilocarpine or nicotine were unaffected (Feldberg and Toh, 1953; Rapport and Koelle, 1953; Rocha e Silva et al., 1953) . Gaddum and Hameed (1954) postulated that there must be two types of receptors on the enteric parasympathetic ganglia, which responded to either serotonin or nicotine. It was also reported that the vasoconstrictor effect of serotonin on the rabbit ear artery was not much affected by piperoxan, atropine or cocaine, was moderately antagonized by dibenamine and gramine, but was potently blocked by lysergide, dihydroergotamine or ergotamine.
EARLY SEROTONIN RECEPTOR CLASSIFICATIONS

Gaddum's 'M' and 'D' Serotonin Receptors
A vital step towards characterization of serotonin receptors was undertaken by Gaddum and Picarelli (1957) , who reported that the serotonin-induced guinea-pig ileum contraction was only partially blocked by either morphine or dibenzyline (phenoxybenzamine), but was completely antagonized by the combined use of the two compounds. Furthermore, lysergide, 2-bromolysergide and dihydroergotamine completely antagonized the response to serotonin in the morphine-treated ileum, and the same was true for atropine and cocaine in the dibenzyline-treated ileum. It was concluded, therefore, that serotonin activated two different types of receptors: an 'M' serotonin receptor, located on the parasympathetic ganglion and mediating acetylcholine release from postganglionic nerve endings, and a 'D' serotonin receptor, located on smooth muscles and directly contracting the muscle (Fig. 1) . However, it may be noted that the interference of the contractile effect of serotonin by morphine and atropine was due to the inhibition of acetylcholine release (see Saxena, 1970) and its interaction with the muscarinic receptor, respectively; only cocaine proved to be a weak 'M' serotonin receptor antagonist (see Fozard, 1990) , while phenoxybenzamine acted as an unspecific antagonist.
For a long time, no potent and selective antagonist at 'M' serotonin receptors was reported, but a number of compounds (e.g. cyproheptadine, lysergide, methysergide, pizotifen, mianserin) became known as 'D' serotonin receptor antagonists. 
No&M and No&D Serotonin Receptors
Despite the 'M' and 'D' serotonin receptor classification becoming widely accepted, there were some responses to serotonin which could not be placed within this scheme. For example, in the early 1970s it was reported that the 'D' receptor antagonists, mianserin and cyproheptadine, failed to antagonize the vasoconstrictor effect of serotonin in the canine external carotid arterial bed (Fig. 2) . Therefore, it was concluded that the serotonin receptors in the external carotid vascular bed of the dog were of a 'special' type and could not be categorized as either 'M' or 'D' type (Saxena et al., 1971; Saxena, 1972; Saxena and De Vlaam-Schluter, 1974 (Bennett and Snyder, 1976; Fillion et al., 1978) . However, further studies with [3H]serotonin, ['Hlspiperone and ['Hjlysergide enabled Peroutka and Snyder (1979) to suggest the existence of two distinct serotonin 'receptors'-a 5-HT, 'receptor' (high nanomolar affinity for serotonin) and a 5-HTz 'receptor' (high affinity for spiperone and low micromolar affinity for serotonin). Subsequently, Pedigo et al. (1981) reported that the 5-HT, binding site could be subdivided into 5-HTIA and 5-HTu, subtypes on the basis of high and low affinity, respectively, for spiperone. Soon, 8-OH-DPAT was recognized as a selective ligand for the 5-HTIA subtype (Middlemiss and Fozard, 1983) . This subdivision of the 5-HT, binding site continued into 5-HT,e (Pazos et al., 1984) , 5-HT,u (Heuring and Peroutka, 1987) , 5-HTIE (Leonhardt et al., 1989 ) and 5-HTkF Adham et al., 1993) subtypes; the 5-HT,u subtype itself also appeared to be heterogeneous (Sumner and Humphrey, 1989) . Saxena (1972) .
MODERN SEROTONIN RECEPTOR CLASSIFICATION
Development of a Framework
The need for a uniform terminology for serotonin receptors was apparent, since these receptors were being referred to by various names ('D , ' 'M', 5-HT,, 5-HT2, S,, SZ etc.) (Humphrey, 1983; Verdouw et al., 1984) . Indeed, it was suggested that the old serotonin receptor classifications "should give way to a new classification based on a 5-HTI, 5-HT2, 5-HT, series. . . the 5-HT receptors subserving arteriolar dilatation, presynaptic inhibition of sympathetic transmission, autoinhibition in the brain and possibly constriction of arteriovenous anastomoses, could be termed 5-HT,. The receptors mediating vaso-and broncho-constriction and platelet aggregation could be called 5-HT, receptors and those mediating ganglionic stimulation, the Bezold-Jarisch reflex and catecholamine release in the heart should be designated as 5-HT3 receptors in place of 'M' receptors. As there are many effects of 5-HT which await classification. . . this series could, if needed, be extended by using both numbers and letters (as additional subscripts)" (Verdouw et al., 1984) .
In 1986, a group of scientists formulated criteria for the characterization, and a general framework for the nomenclature of serotonin receptors. From the beginning, it was obvious that either of the two previous classifications proposed by Gaddum and Picarelli (1957) and Peroutka and Snyder (1979) were incomplete, but did complement each other. Therefore, it was decided to build upon these two classifications, taking into account rank order and ligand binding affinities of the agonists and antagonists, with some consideration of the second messenger systems involved. Thus, serotonin receptors were classified into three main categories: 5-HT,-like (corresponding to some 'D' receptors and 5-HT, binding sites), 5-HTz (corresponding to most 'D' receptors and 5-HTz binding sites) and 5-HT3 (equivalent to 'M' receptors) (Bradley et al., 1986) . The important criteria for classification were: 5-HT,-like receptors-5-carboxamidotryptamine, generally a more potent agonist than serotonin, high affinity for the antagonist methiothepin, but not for ketanserin or ICS 205-930 (tropisetron); 5-HT2 receptors-high affinity for the agonist a-methyl-5-HT and antagonists ketanserin and methiothepin, but not for tropisetron, coupling to phosphatidylinositol turnover; and 5-HT, receptors-high affinity for the agonist 2-methyl-5-HT and antagonist tropisetron, but not for ketanserin or methiothepin, part of cation channels. It was clearly pointed out that the 5-HT&ke receptors were heterogeneous and that some serotonin responses, e.g. the tachycardia in the pig (Duncker et al., 1985) , still defied classification. Shortly thereafter, 5-HT, recognition sites were described in the brain (Kilpatrick et al., 1987) and evidence in favour of 5-HT., receptors began to emerge (see Saxena, 1986; Born et al., 1988; Dumuis et al., 1988 Dumuis et al., , 1989 .
Cloning of Serotonin Receptors
Since the original scheme of serotonin receptor classification was proposed (Bradley et al., 1986) an enormous amount of new information on the molecular biology of serotonin receptors has become available. Several receptors have now been cloned and expressed in cells, and the amino acid sequence and structure of the receptor protein, as well as the gene involved, have been determined. Furthermore, using second messenger responses in the host cell, agonists' and antagonists' rank order of the recombinant serotonin receptors has been compared with that of the native receptors. This process has led to identification of several serotonin receptor clones (Table 1 ). In the case of 5-HT4 receptors, the clones have two splice variants: a short form with 387 amino acids (5-htds) and a long form with 407 amino acids (5-ht4,_) . Both these forms show similar pharmacology (Adham et ul., 1995) but the functional effects have not been established yet.
Approach to Receptor Classification
The knowledge accumulating from molecular biological work compels reconsideration of conceptual thinking behind receptor classification (Hoyer et al., 1994) not only in the case of serotonin, but for other neurotransmitters. The Nomenclature Committee of the Serotonin Club, which evolved the Bradley Classification of serotonin receptors (Bradley et al., 1986) , once again assigned itself this task. After a brief report of its deliberations ) a detailed version approved by the main IUPHAR Committee for Receptor Nomenclature has been published recently (Hoyer et al., 1994) .
The IUPHAR receptor nomenclature committee has advocated a number of criteria for receptor classification (Kenakin et al., 1992) , and these have been extended by the Nomenclature Committee of the Serotonin Club (Hoyer et al., 1994) . As shown in Table 2 , these criteria fall into three categories: operational (selective agonists, selective antagonists and ligand binding affinities), structural (molecular structure of the receptor protein and, thus, the extent of homology) and transductional (intracellular receptor-effecter coupling mechanism). Together, these provide a 'finger-print' basis for identifying distinct receptors.
It is undeniably true that the structure of the receptor protein is the mark of true identity of the receptor. However, it is equally important to realize that substantial changes in the amino acid sequence may not affect (e.g. in the case of 5-HT,, and 5-HTID, receptors), while little alteration may cause vast changes in the operational characteristics of a receptor (e.g. in case of species homologous 5-HTje and 5-HTloa receptors) .
Two other important recommendations have been made by Hoyer et al. (1994) . Firstly, in keeping with the earlier suggestion (Kenakin et al., 1992) , it has been advised to use lower case letters for recombinant receptors with little knowledge of operational characteristics (e.g. 5-ht, receptor) and upper case letters for reasonably well-characterized native receptors (e.g. 5-HTz receptor). Secondly, since not all necessary criteria, as outlined in Table 2 , are always available, it is probably not possible to obtain a fully rationale classification scheme. Therefore, it is necessary to hold certain receptors provisionally in an 'orphan' category awaiting further characterization.
The Present Classification of Serotonin Receptors
Based on the general criteria mentioned in Table 2 
1993
Abbreviation-nAA, (predicted) number of amino acids.
Operational Table 2 . The above data provide a 'finger-print' basis on which to identify and classify distinct receptors. Adapted from Hoyer et al. (1994) . and 5-HT4 receptors), with certain recombinant (5-ht,,,, 5-htlD,, 5-ht,,, 5-htlF, 5-htds, 5-h& 5-ht,,, 5-htjB, 5-h&, and 5-ht,) and 'orphan' receptors ( Fig. 3) . The specific operational, structural and transductional properties of the different serotonin receptors are shown in Table 3 (Hoyer et al., 1994) . Structurally, all serotonin receptors, except the 5-HT3 receptor, which forms a part of cation channels, belong to the G-protein superfamily and contain the characteristic seven transmembrane regions. All 5-HT, receptors are negatively coupled to adenylyl cyclase; all 5-HTz receptors, including the previously called 5-HT,, receptor (hence renamed 5-HTzc), are coupled to protein kinase C via increased phosphoinositide breakdown, while the 5-HT+ 5-h& and 5-ht, receptors are positively linked to adenylyl cyclase.
Criteria for Receptor Characterization and Classification
Structural
SEROTONIN RECEPTORS I
Except for the recombinant subtypes 5-htlE and 5-htlF (which have been placed in the group based on structural homology and transductional similarity), operationally all other 5-HT, receptors have high affinity for 5-carboxamidotryptamine as agonist and methiothepin as antagonist. It should be noted that such operational criteria also apply to the 'orphan' receptor mediating smooth muscle relaxation; indeed, it was known previously as the sumatriptan-insensitive 5-HT,-like (or 5-HTIU) receptor (Bradley et al., 1986; Saxena and Villalon, 1990a) . However, in view of its positive coupling to adenylyl cyclase, this receptor, which may turn out to be identical to the recombinant 5-ht, receptor (Bard et af., 1993; Plassat et al., 1993) , has been placed in the 'orphan' category. The 5-HTIA receptor has a high and selective agonist affinity for flesinoxan, 8-OH-DPAT and dipropyl-5-carboxamidotryptamine, the 5-HT,, receptor has a high selective agonist affinity for CP 93,129, while both 5-HT,, and 5-HTJike receptors have a relatively high affinity for sumatriptan. Selective antagonists have only recently been described for 5-HT,, (WAY 100135; Fletcher et al., 1993) and 5-HT,, (GR 127935; Skingle et al., 1993; Clitherow et al., 1994) receptors, and undoubtedly, these will help in further characterization. With regard to the 5-HT,-like receptors, it is to be noted that their structure has not been elucidated yet (Table 3) and that these may be heterogeneous (see Saxena and Villalon, 1990a; Hoyer et al., 1994) . The operational characteristics of 5-HT,-like receptors resemble those of 5-htlo, and 5-ht,n, receptors, and it is possible that some 5-HT,-like receptors may turn out to be identical to these or other recombinant receptors. The operational characteristics of 5-HT2 receptor subtypes are similar, but not identical; ketanserin seems to be much more potent at the 5-HTZA receptor than at the two other subtypes. In the case of the 5-HT3 and 5-HT4 receptors, potent and selective antagonists are now available.
RESPONSES MEDIATED BY SEROTONIN RECEPTORS
The functional responses associated with the different 5-HT, receptor subtypes are listed in Table 4 . The 5-HT,, receptor stimulation is associated with behavioural changes and a centrally mediated hypotensive response. The 5-HTle receptor is present in the rodent CNS and seems primarily associated with decrease in transmitter release. The same appears to be the case with 5-HT,n receptors in other mammals. In addition, it is suggested, though not definitely established yet, that stimulation of 5-ht,,, receptor decreases plasma extravasation following trigeminal nerve stimulation (Buzzi et al., 1991; Matsubara et al., 1991) , while 5-ht ,nB receptors mediate contraction of cerebral arteries (Hamel et al., 1993) . The contraction of cephalic arteries and arteriovenous anastomoses and inhibition of noradrenaline release from sympathetic nerve endings are mediated by 5-HT,-like receptors, but some 5-HT,-like receptors may be identical to the 5-HT,n receptors (Hoyer et al., 1994) . Table 5 present examples of functional responses mediated by 5-HTz, 5-HT, and 5-HT4 receptors. The 5-HTzA receptor is ubiquitous and mediates mainly contraction of vascular and nonvascular smooth muscles, platelet aggregation and neuroexcitation. The 5-HTZB receptor has been located primarily in the rat and mouse stomach fundus and mediates contraction. The 5-HT,, receptor may regulate the amount and composition of the cerebrospinal fluid, as well as decrease locomotion and appetite. Undoubtedly, the 5-HT1 receptor is involved in vomiting resulting from radiation and anticancer drugs. In addition, stimulation of the 5-HTj receptor, which is a part of a cation channel, results in depolarization of peripheral and central neurons. Stimulation of the 5-HT4 receptor leads to decreases in K+ conductance in colliculi neurons and increases in EEG energy. Peripherally, 5-HT4 receptors affect motility of the gastrointestinal tract and mediate increases in the porcine and human atria1 rate and contractility (Table 5) . Interestingly, 5-HT4 receptors seem to be absent on porcine Schoemaker et al., 1992) , as well as human (Jahnel et al., 1992; Schoemaker et al., 1993) ventricles.
The structure of the recombinant 5-htsA, 5-ht,,, 5-hts and 5-ht, receptors is well-established, and these have been localized mainly in certain areas of the CNS, but the functions mediated are yet to be understood (Table 6 ). On the other hand, a number of serotonin receptors have been placed in a temporary 'orphan' category, since no structural data and only limited transductional and operational data are available yet (Table 6 ).
THERAPEUTIC USES OF SEROTONIN RECEPTOR LIGANDS
There are currently more than 70 pharmaceutical companies with interest in serotonergic drugs, and the leaders, in the rank order of the number of patents filed (and not the revenue earned), are shown in Fig. 4 . This patent activity indicates that these companies expect to convert the new chemical entities into marketable products for therapeutic uses. The established, as well as some potential, therapeutic uses of serotonin receptor agonists and antagonists are listed in Table 7 .
Anxiety States
The role of serotonin uptake inhibitors, as well as serotonin receptor ligands, in the treatment of anxiety states has been explored extensively (see Charney et al., 1990; Murphy et al., 1993 ). It appears that 5-HTIA receptor partial agonists such as buspirone are clinically effective in generalized anxiety disorders and in anxiety associated with depression, but not in panic disorders. The effectiveness of these drugs in obsessive anxiety disorders has been investigated so far in only one controlled trial (see Murphy et al., 1993) . Animal experiments suggest that 5-HTIA receptors located in the hippocampus, thalamus, amygdala and rapht nuclei are involved in the therapeutic effects of 5-HTIA receptor partial agonists in anxiety (Charney et al., 1990) . Clinical results with the recently developed Abbreviations-Ach, acetylcholine; AVAs, arteriovenous anastomoses; BP, arterial blood pressure; EDRF, endothelium-derived relaxant factor (probably nitric oxide); HR, heart rate; NA, noradrenaline.
'silent' 5-HTIA receptor antagonists, such as WAY 100135 (Fletcher et al., 1993) , are awaited with interest to settle the question whether an agonist or antagonist activity is important in the anti-anxiety effect. Some preliminary clinical trials suggest that 5-HT2 and 5-HT, receptor antagonists may have a beneficial effect in generalized anxiety disorder patients (Murphy et al., 1993; Greenshaw, 1993 ). Fozard, 1990 Villalon, 1990a Fozard, 1990; Villalon, 1990a Fozard, 1990; Villalon, 1990a Orwin and 1990, 1991) 'Based on Hoyer et al. (1994) ; 2porcine ventricles lack S-HT4 receptors (Saxena et al., 1992; Schoemaker et al., 1992); )human left ventricles lack S-HT., receptors (Jahnel et al., 1992; Schoemaker et al., 1993) .
Abbreviations-CSF, cerebrospinal fluid; EPSP, excitatory postsynaptic potential. Abbreviations-Ach, acetylcholine; EDRF, endothelium-derived relaxant factor (probably nitric oxide); NA, noradrenaline.
Based on Saxena and Villalbn (1990a) and Hoyer et al. (1994) . Cardiac arrhythmias Preclinical 'cl-Adrenoceptor antagonist activity is apparently more important; 2other actions are involved; 'other properties probably are also involved.
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Abbreviations-IBS, irritable bowel syndrome. hydrochloride; WAY 100135, N-tert-butyl-3-(4-[2-methoxyphenyl]pipern-l-yl)-2-phenylpropanamide dihydrochloride. Goldberg and Finnerty, 1979; Goa and Ward, 1986 Glasser, 1988 Costello et al., 1991; Pecknold et al., Ramage, 1986 Kolassa et al., 1993; Saxena and Villalon, 1990b Fletcher et al., 1993 Ferrari and Saxena, 1993 Saxena and Tfelt-Hansen, 1993; Welch, 1993 Connor et However, the evidence so far is far from compelling, and the results of larger placebo-controlled clinical trials are awaited.
Other Central Nervous System Diseases
Drugs acting on serotonin receptors can have potential use in several other CNS diseases, like depression, schizophrenia, memory impairment, sleep disorders and substance abuse (see Table 7 ). Since 5-HT,n receptors have been located at serotonergic nerves and can inhibit the transmitter release, antagonists at these autoreceptors may increase serotonin release and, thus, have antidepressant activity. The 5-HTz receptor antagonists, ritanserin and risperidone, which also blocks dopamine receptors, are being explored for use in psychosis and sleep disorders (Castelao et al., 1989; Westenberg and Den Boer, 1989; Min et al., 1993) . Lastly, clinical investigations with 5-HTI receptor antagonists are being performed in schizophrenia, substance abuse and memory impairment (see Preston et al., 1992; Costa11 et al., 1993; Greenshaw, 1993; Hagan et al., 1993) . Results of more extensive and controlled clinical trials are awaited with great interest.
Migraine
A large number of studies has shown conclusively that sumatriptan, an agonist at 5-HT,-like receptors, is effective in aborting migraine attacks (see Ferrari and Saxena, 1993; Saxena and Tfelt-Hansen, 1993; Welch, 1993) . The success of this drug, both in a clinical and economic sense, has prompted a large number of pharmaceutical companies-Bristol-Myers Squibb (Smith et al., 1992) , Glaxo Johnson and North 1993; Perren et al., 1993) Merck Sharp and Dohme ), Merrel Dow (McDonald et al., 1992 Wellcome Foundation (King et al., 1993a) and others-to try to develop novel 5-HT,-like receptor agonists. In particular, the efforts are directed to make more lipid-soluble and selective compounds to improve oral bioavailability and avoid coronary artery vasoconstriction. High lipid solubility can turn out to be a double-edged weapon, since such molecules, unlike sumatriptan (Dallas et al., 1989) . would be expected to readily cross the blood-brain barrier and may then be associated with a higher incidence of unwanted effects. For example, in the case of compounds with a similar receptor profile as sumatriptan, the 5-HT,, receptor agonism may lead to hypotension and bradycardia (see Saxena and Villalon, 1990a,b) .
It is argued sometimes that sumatriptan owes its therapeutic activity solely to a presynaptic action, which inhibits neuropeptide releases and, therefore, 'neurogenic' inflammation (Moskowitz, 1993) . Though this view is not shared universally (see Saxena and Ferrari, 1989; Humphrey and Feniuk, 1991; Ferrari and Saxena, 1993; Saxena and Tfelt-Hansen, 1993) , it is of interest to note that NK, receptor antagonists, such as RP 67580 (Shepheard et al., 1993) have been found far more potent than 5-HTle:n receptor agonists (CP 93,129 and sumatriptan) in blocking neurogenic plasma extravasation following trigeminal ganglion stimulation. Should such compounds prove effective as antimigraine agents, the involvement of 'neurogenic' inflammation in migraine will have a stronger footing, though it will not be regarded as an argument against the involvement of vascular mechanisms (Saxena and Ferrari, 1989; Humphrey and Feniuk, 1991; Ferrari and Saxena, 1993; Saxena and Tfelt-Hansen, 1993) .
Some antimigraine drugs are potent antagonists at 5-HT,, receptors (methysergide. pizotifen, ergotamine, dihydroergotamine), but many other such agents (ketanserin, ritanserin, cyproheptadine, mianserin, methiothepin, metergoline, sergolexole, ICI 169, 369) have not been found of much use in migraine therapy (Winther, 1985; Davies and Steiner, 1990; Tfelt-Hansen and Pedersen, 1992; Tfelt-Hansen and Saxena, 1993) . It seems, therefore, that additional properties of these antimigraine drugs, for example, the vasoconstriction in the extracerebral cephalic circulation with methysergide, ergotamine and dihydroergotamine (partly via 5-HT,-like receptors) and the antidepressant action with pizotifen, may be involved in their therapeutic action . Based mainly on the ability of a 5-HT,e receptor agonist, m-chloro-phenyl piperazine, to elicit migraine-like headaches in some patients and the ability of drugs such as mianserin to block this receptor, it has been advocated that 5-HTZc receptor antagonism is important for antimigraine action (Fozard and Gray, 1989; Fozard, 1992; Kennett, 1993) . It should be noted, however, that m-chloro-phenyl-piperazine is not a selective agent and drugs that block the 5-HTzc receptor (e.g. mianserin, sergolexole) are not particularly effective against migrainous headaches. Moreover, rather than being antagonists, the antimigraine drugs ergotamine and dihydroergotamine behave as potent agonists at the 5-HTlc receptor (Brown et al., 1991) .
Despite the fact that many 5-HT3 receptor antagonists are known for several years and three of them (ondansetron, granisetron and tropisetron) are in clinical use for the treatment of vomiting induced by anticancer drugs, only two such drugs (MDL 72222 and granisetron) have been reported to be effective in migraine (Loisy et al., 1985; Couturier et al., 1991) . Though MDL 72222 was studied in a double-blind, placebo-controlled manner (Loisy et al., 1985) , this study has been flawed on several grounds (Ferrari, 1991; Ferrari et al., 1991) . Granisetron was evaluated in an open study on six patients (Couturier et al., 1991) and, despite encouraging results, this study was discontinued, according to the investigators "for extraneous reasons". On the other hand, carefully designed and extensive investigations with tropisetron, both as acute and prophylactic migraine therapy, were largely negative (Ferrari, 1991; Ferrari et al., 1991) . Since no other positive results are known with any of the 5-HT, receptor antagonists, it must be concluded that this receptor does not play a major role in migraine.
The above analysis strongly suggests that within the bounds of serotonergic mechanisms, the antimigraine action mainly depends upon an agonist action at the 5-HT,-like receptor subtype that mediates cephalovascular constriction (Saxena et al., 1993).
Vomiting
Nausea and vomiting are extremely unpleasant side effects of anticancer drugs, and the dopamine D2 receptor antagonists are not very effective as antiemetic agents. Following the report that high doses of metoclopramide, which also blocks 5-HT3 receptors (Bradley et al., 1986; Fozard, 1990) can prevent cisplatin-induced vomiting in cancer patients (Gralla et al., 1981) , it was realized that 5-HT, receptor blockade may play an important role in vomiting (Miner and Sanger, 1986 1990 ) have all been shown to successfully suppress the acute phase of vomiting caused by cisplatin; unfortunately, the delayed phase is not much affected (see Wells et al., 1993) . The 5-HT3 receptor antagonists are selectively effective against vomiting following cancer chemotherapy, radiation exposure or general anaesthesia; these drugs do not prevent vomiting due to other causes, such as motion sickness.
The mechanism of antiemetic action of 5-HTs receptor antagonists appears to be at the level of sensory vagal nerve terminals in the gastrointestinal mucosa, with a possible additional effect at the chemoreceptor trigger zone, where 5-HT3 receptors have also been localized (Kilpatrick et al., Wells et al., 1993) . Microdialysis measurements have clearly shown that cisplatin increases serotonin levels in the ileum, as well as the blood, and such increases are accompanied by vomiting episodes (Fukui et al., 1993) .
Hypertension
Both urapidil (5-HTIA receptor agonist) and ketanserin (5-HTzA receptor antagonist) have been approved for the treatment of hypertension. Indeed, it is claimed that these drugs decrease blood pressure by stimulating 5-HT,, receptors located centrally in the nucleus tractus solitarus (urapidil) or by blocking 5-HT,, receptors mediating peripheral vasoconstriction (ketanserin). However, as discussed in detail elsewhere (Saxena and Wouters, 1990 ) it does not appear that such effects are involved to a significant degree in the clinical effects of these drugs; both urapidil and ketanserin have a potent a,-adrenoceptor antagonist activity, which can adequately explain the antihypertensive effect (see Saxena and Villalon, 1990b ).
Gastric Motility Disorders
It is well known that high concentrations of serotonin are present in the gastrointestinal tract, where it appears to play an important physiological role in the peristaltic movements (see Gershon et al., 1991) . Although some progress has been made towards delineation of the nature and function of serotonin receptors in the gastrointestinal tract of several animal species (Dhasmana et al., 1993) , the knowledge with regard to the human gut is still scant (Talley, 1992; Tam et al., 1992; McLean et al., 1993) . However, 5-HT3 and 5-HT4 receptor antagonists are being explored for therapeutic use in irritable bowel syndrome (Prior and Reed, 1993) since these drugs slow colonic transit in healthy volunteers (Gore et al., 1990; Talley et al., 1990) .
The 5-HT4 receptor agonists seem to have a prokinetic effect (Briejer et al., 1993; Gullikson et al., 1993; King et al., 1993b; Stacher et al., 1993) , and their use in reflux oesophagitis (Geldof et al., 1993) and idiopathic (Corinaldesi, 1993) and diabetic (Kawagishi et al., 1993) gastroparesis is being advocated.
Pain
Recent preclinical studies suggest that 5-HT is involved in the mediation of pain, but it has multiple and opposing effects, which depend upon the location and the type of receptor involved (Greenshaw, 1993) .
Within the superficial dorsal horn of the spinal cord, a dense band of 5-HT, receptors has been located on capsaicin-sensitive primary afferent nerve terminals. These 5-HT, receptors mediate an antinociceptive effect against intrathecal application of substance P and N-methyl-D-aspartate, possibly via y-aminobutyric acid release (Alhaider et al., 1991) . In contrast, peripheral 5-HTj receptors mediate an algesic response following topical application of serotonin on blister base in humans (Richardson et al., 1985; Fozard, 1990) .
The nociceptive response to i.v. serotonin may be mediated by both 5-HTz and 5-HT3 receptors located on capsaicin-sensitive vagal nerve afferents and, therefore, a combined use of 5-HT? and 5-HT, receptor antagonists has been suggested for the relief of pain in angina pectoris and other peripheral vascular disorders (Mellor et al., 1992) . Interestingly, both 5-HT, and 5-HT? receptors mediate human coronary artery constriction induced by 5-HT (Connor et al., 1989a; Chester et al., 1990; Bax et al., 1993) , as well as platelets, even after cyclooxygenase inhibition with aspirin (Bax et al., 1994) . Thus, it is advocated that a combined use of 5-HT, and 5-HTz receptor antagonists may have some role in the treatment of angina pectoris (Bax et al., 1994) .
Cardiac Disorders
Increases in the rate and contractility in the human atrium are mediated by 5-HT4 receptors (see Table 5 ). Serotonin can induce arrhythmias in the human isolated atrium and, therefore, 5-HT4 receptor antagonists could be useful in the treatment of cardiac arrhythmias (Kaumann and Sanders, 1994) . However, it is not established yet if serotonin plays any role in the pathogenesis of cardiac arrhythmias.
The increase in atria1 contractility by 5-HT4 receptor agonists indicated that such drugs may have application in the therapy of heart failure. Any such hope has now been dashed, as recent investigations indicate that 5-HT, receptors are not present on human ventricles (Jahnel et al., 1992; Schoemaker et al., 1993) .
CLOSING REMARKS
During the last decade, research in the field of serotonin has been boosted by the availability of potent and selective drug tools. These drug tools and increasing understanding of the transduction mechanisms, as well as the structure of the receptor protein, have enabled the characterization and nomenclature of serotonin receptors in a more meaningful way. Thus, four main classes with several subtypes ) , as well as some recombinant (e.g. 5-ht,,, 5-htse, 5-ht,, 5-ht,; note the use of lower case alphabets) and 'orphan' serotonin receptors, have been recognized. The suggestions made by the Nomenclature Committee of the Serotonin Club and the criteria used in classifying serotonin receptors undoubtedly will be helpful to other groups involved in the classification of pharmacological receptors.
The molecular cloning and expression of a growing number of serotonin receptors in host cells now offers the possibility to screen new molecules relatively easily in order to recognize more selective ligands. However, this development poses new challenges. Obviously, one of the challenges involves the understanding of the precise function of the recombinant receptors at the various anatomical locations. Secondly, it may be asked why should there be so many serotonin receptor subtypes in the body. Is it that each receptor subtype mediates a specific function, or is it that more than one receptor subtype mediates the same function, perhaps under different circumstances, thus providing 'receptor backup'? The answers will dictate the strategy with regard to the degree of selectivity in developing therapeutically relevant molecules.
The responses mediated via many serotonin receptors are now well understood, and this, in turn, has resulted in the development and use of serotonergic drugs in the therapy of several diseases, including anxiety and migraine. Given the pace with which new knowledge is emerging, therapeutic potentials of serotonin-based drugs will undoubtedly be exploited further. The availability of newer and more selective serotonin iigands will help us better define the role of serotonin and its receptors in physiological processes and pathophysiological mechanisms. This knowledge, in turn, will provide access to better drugs for treatment of human ailments more efficiently. Thus, the future of serotonin research looks as bright as ever.
